Gilead Sciences has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the FDA’s rapid review and acceptance of Gilead’s IND filing. Enrollment of the clinical trial began in March — at present, 1000 participants will be entered into the trial. Yourway is committed to advancing trials and has full DTP capacity, which is particularly relevant given the stay-home-orders in place across countries and states.